Copley Acquisition Corp and Ignite Proteomics Announce Definitive Business Combination Agreement to Advance Precision Oncology

Copley Acquisition Corp (NYSE: COPL), a special purpose acquisition company, and Ignite Proteomics, LLC, a company focused on pathway-level protein analytics for precision oncology, have entered into a definitive business combination agreement. Upon closing, Copley and Ignite Proteomics will become wholly owned subsidiaries of a new public holding company, Ignite Proteomics Holdings, Inc., which will be listed on the New York Stock Exchange. The transaction values Ignite at a $150 million pro forma enterprise value and is expected to close in the second half of 2026.